Interestingly, high expression of GPX1 and SLC16A1 was associated with a poor OS for metastatic PCa patients from the SU2C-PCF dataset (HR = 2.09, Cox p = 0.029, for GPX1; HR = 3.973, Cox p < 0.0001, for SLC16A1) (Figure 3F), while high expression of SLC39A1 correlated with a better prognosis (HR = 0.427, Cox p = 0.037) (Figure 3F). This evidence concerns the gene SLC16A1 and posterior cortical atrophy.